ProQR Therapeutics NV (MEX:PRQRN) Total Stockholders Equity: MXN1,597.7 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PRQRN ProQR Therapeutics NV MEX:PRQRN
50 GF Score
Price MXN36.00
GF Value MXN39.89
! 2 Warning Signs
View Full Analysis

What is ProQR Therapeutics NV Total Stockholders Equity?

ProQR Therapeutics NV MEX:PRQRN 50 Total Stockholders Equity is MXN1,597.7 Mil as of Jun. 2026. GuruFocus rates MEX:PRQRN with a GF Score™ of 50/100 and a GF Value™ of MXN39.89. The stock has 2 warning signs investors should review.

ProQR Therapeutics NV's Total Stockholders Equity for the quarter that ended in Jun. 2026 was MXN1,597.7 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. ProQR Therapeutics NV's Book Value per Share for the quarter that ended in Jun. 2026 was MXN11.32. The ratio of a company's debt over equity can be used to measure how leveraged this company is. ProQR Therapeutics NV's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.19.

ProQR Therapeutics NV  (MEX:PRQRN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

ProQR Therapeutics NV's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1597.689-0)/141.119
=11.32

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

ProQR Therapeutics NV's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(133.079 + 174.731) / 1597.689
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV Total Stockholders Equity Related Terms

ProQR Therapeutics NV Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for ProQR Therapeutics NV's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV Total Stockholders Equity Chart

ProQR Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,638.61 1,385.06 766.16 1,934.01 1,041.00

ProQR Therapeutics NV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,454.71 1,228.78 1,041.00 783.81 1,597.69
MEX:PRQRN
50GF Score
ProQR Therapeutics NV MEX:PRQRN
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of MXN1,597.7 Mil mean?
ProQR Therapeutics NV (MEX:PRQRN) has a Total Stockholders Equity of MXN1,597.7 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for ProQR Therapeutics NV and its competitors.
Is ProQR Therapeutics NV's Total Stockholders Equity too high?
ProQR Therapeutics NV's current Total Stockholders Equity is MXN1,597.7 Mil. Overall, ProQR Therapeutics NV has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's Total Stockholders Equity compare to NWBO and IMRX?
ProQR Therapeutics NV's Total Stockholders Equity of MXN1,597.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current Total Stockholders Equity is MXN1,597.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
ProQR Therapeutics NV (MEX:PRQRN) has a current Total Stockholders Equity of MXN1,597.7 Mil. The stock's GF Value™ is MXN39.89, compared to a current price of MXN36.00 — trading 9.8% below its estimated fair value. The current Total Stockholders Equity is MXN1,597.7 Mil. ProQR Therapeutics NV's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current Total Stockholders Equity is MXN1,597.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of MXN36.00 is trading 9.8% below its estimated GF Value™ of MXN39.89.

Key valuation signals for MEX:PRQRN:

  • Total Stockholders Equity: MXN1,597.7 Mil
  • GF Value™: MXN39.89 vs. price of MXN36.00 (9.8% below fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ProQR Therapeutics NV Business Description

Other Exchanges PRQR:USA0PQ:Germany
Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
50GF Score

Get the complete analysis for MEX:PRQRN

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN36.00
Price
MXN39.89
GF Value